Autolus Therapeutics (ADR) (AUTL)
Commercializes AUCATZYL while developing programmed T-cell therapies for cancer and autoimmune diseases.
Something off on this page? Send us feedback.
Sells AUCATZYL, an autologous CAR-T therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The early commercial business is centered on US delivery, with a UK launch and an EU rollout subject to local access decisions.
Built around autologous CAR-T cell therapy, the business sells AUCATZYL for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States. Its first US sale marked the shift from a clinical platform to early commercial delivery.
Research continues on next-generation programmed T-cell therapies for cancer and autoimmune diseases, rooted in a University College London spinout founded by Martin Pule. Operations span London and a US office in Maryland.
Market access differs by region: AUCATZYL launched in the UK through NHS commissioning, while an EU launch remains on hold during pricing and market-feasibility evaluation. Regulatory authorization and country-specific access decisions shape expansion.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Nov 18, 2024 | Goldman Sachs | Upgrade | Target: — | Target: $7.60 |
| Nov 15, 2024 | Redburn Atlantic | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $201.6M · Total debt $83.5M · Total assets $493.2M · Shareholders' equity $74.8M
- Revenue
- $45.7M
- Operating income
- −$43.8M
- Net income
- −$39.1M
No dividends on record.
| Institutions | 49.67% | 132.21M ADS | |
|---|---|---|---|
| 86 holders · as of Jun 30, 2026 | |||
| Insiders | 0.54% | 1.43M ADS | |
| 5 holders · as of Sep 3, 2026 | |||
| Other | 49.79% | 132.53M ADS | |
| remainder | |||
266.16M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mak Capital One LLCInstitution | 12.63% | 33.62M ADS | as of Jun 30, 2026 |
MAK Capital Fund LPInstitution | 12.63% | 33.62M | filed May 15, 2026 |
Blackstone Inc.Institution | 7.70% | 20.49M ADS | as of Jun 30, 2026 |
Syncona Portfolio LtdInstitution | 6.25% | 16.64M ADS | as of Jun 30, 2026 |
Armistice Capital, LLCInstitution | 5.64% | 15.00M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Cintia Piccina | officer: U.S. CCO & Country Gen Manager | −6,713 | $2.34 |
- Gilead Sciences
Adult r/r B-cell precursor ALL CAR-T alternative
- Amgen
CD19 bispecific therapy in r/r B-cell precursor ALL
- Pfizer
CD22 antibody-drug conjugate in r/r B-cell precursor ALL
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Autolus Therapeutics (ADR) | $2.09 | +2.30% | $516.3M | — | — | 4.4 | +118.4% |
| Gilead Sciences | $151.50 | −0.77% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Amgen | $410.19 | −0.00% | $212.19B | 24.4 | 17.5 | 5.6 | +9.7% |
| Pfizer | $27.91 | −0.07% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Median | 30.5 | 16.8 | 5.6 | +9.7% |